BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Enanta Pharmaceuticals, Inc. 

500 Arsenal Street

Watertown  Massachusetts  02472  U.S.A.
Phone: 617-607-0800 Fax: 617-607-0530


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
Enanta Pharmaceuticals, Inc. To Present At Barclays Global Healthcare Conference 3/4/2015 11:11:03 AM
Enanta Pharmaceuticals, Inc. Announces JAMA Publication Of Results From AbbVie (ABBV)’s Study Of VIEKIRA PAK™ (Ombitasvir, Paritaprevir, Ritonavir Tablets; Dasabuvir Tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) 2/23/2015 11:21:14 AM
Enanta Pharmaceuticals, Inc. Announces AbbVie (ABBV) Submits New Drug Application To The Japanese Ministry Of Health, Labour And Welfare For Its Investigational, All-Oral, Treatment For Chronic Hepatitis C 2/12/2015 11:42:00 AM
Enanta Pharmaceuticals, Inc. To Present At 2015 Leerink Global Healthcare Conference 2/5/2015 11:48:12 AM
Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2014 2/5/2015 11:44:11 AM
Enanta Pharmaceuticals, Inc. Announces 95 Percent SVR12 Rate In Abbvie’s Phase 3 Study Of All-Oral Treatment For Hepatitis C Virus In Japanese Patients 2/2/2015 10:58:20 AM
Enanta Pharmaceuticals, Inc. Announces European Commission (EC) Grants Marketing Authorizations For AbbVie (ABBV)’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets)... 1/16/2015 9:50:01 AM
Enanta Pharmaceuticals, Inc. To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/7/2015 9:53:46 AM
Enanta Pharmaceuticals, Inc. Announces FDA Approves AbbVie (ABBV)’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) For The Treatment Of Chronic Genotype 1 Hepatitis C Virus 12/22/2014 12:13:55 PM
Enanta Pharmaceuticals, Inc. Added To The NASDAQ Biotechnology Index 12/15/2014 11:36:51 AM
123456789